NCT00383929已完成3 期
A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate BP Control on Monotherapy With CC 32mg
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,979
- 试验地点
- 2
- 主要终点
- Change (reduction) in sitting BP (24 hours after dose)
研究概览
简要总结
In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5 mg to that of candesartan 32 mg alone in patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and candesartan/HCT 32/12.5 mg with that of candesartan 32 mg, respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of the following criteria:
- •Provision of signed Informed Consent
- •Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs, which the patient and the physician are willing to withdraw at enrolment and change to candesartan monotherapy
- •Mean sitting DBP 90-114 mmHg
- •Patients will be eligible for randomisation (Visit 4) if they fulfil the following criterion:
- •Mean sitting DBP 90-114 mmHg on treatment with candesartan 32 mg monotherapy (after 2 weeks with candesartan 16 mg and 6 weeks with candesartan 32 mg monotherapy). The run-in period should not be shorter than 8 weeks.
排除标准
- •Involvement in the planning and conduct of the study (applies to both AstraZeneca staff, CRO staff or staff at the investigational centre)
- •Pregnant or lactating women, or women of childbearing potential not practising an adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant and verified by a negative pregnancy test at Visit 1
- •Secondary or malignant hypertension
- •Sitting SBP of 180 mmHg or more
- •Patients who are treated with candesartan 16 mg in combination with a diuretic or with candesartan 32 mg with or without any additional antihypertensive treatment
- •Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack within 6 months before enrolment
- •Angina pectoris requiring more treatment than short-acting nitrates
- •Chronic use of NSAIDs
- •Aortic or mitral valve stenosis
- •Cardiac failure requiring treatment
- •Cardiac arrhythmia requiring treatment
- •Renal artery stenosis or kidney transplantation
- •Intravascular volume depletion
- •Hypersensitivity to any component of the investigational products
- •Concomitant disease which may interfere with the assessment of the patient
- •Past or present alcohol or drug abuse, or any condition associated with poor compliance
- •Chronic liver disease or known liver enzyme values above three times the upper limit of the reference range for S-ASAT or S-ALAT
- •Concomitant or previous treatment with other investigational drugs within 20 days of enrolment
- •Previous enrolment in the present study
- •S-creatinine of 180 μmol/l or above for men and of 140 μmol/l or above for women
- •S-sodium or S-potassium outside the reference range
- •Less than 85% compliance with study medication during the run-in phase
研究组 & 干预措施
1
Experimental
Candesartan Cilexetil (CC) /HCT 32/12.5mg
干预措施: Candesartan cilexetil (Drug)
1
Experimental
Candesartan Cilexetil (CC) /HCT 32/12.5mg
干预措施: Hydrochlorothiazide (Drug)
2
Experimental
Candesartan Cilexetil (CC) /HCT 32/25mg
干预措施: Candesartan cilexetil (Drug)
2
Experimental
Candesartan Cilexetil (CC) /HCT 32/25mg
干预措施: Hydrochlorothiazide (Drug)
3
Experimental
Candesartan Cilexetil monotherapy
干预措施: Candesartan cilexetil (Drug)
结局指标
主要结局
Change (reduction) in sitting BP (24 hours after dose)
时间窗: Assessed from baseline (randomisation) to the end of the study.
次要结局
- Proportion of patients with controlled sitting BP in each treatment group(Assessed at the end of the study)
- Occurrence of Adverse Events and discontinuation of study medication due to AEs from baseline (randomisation) to the end of the study(Assessed from baseline (randomisation) to the end of the study.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
MK0954A-264 Filter Study (0954A-264)(COMPLETED)Mild to Severe HypertensionNCT00307060Organon and Co274
已完成
4 期
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes MellitusHypertensionNCT00927394Novartis1,143
已完成
2 期
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential HypertensionHypertension, EssentialNCT01303783Bayer1,381
已完成
3 期
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and PlaceboHypertensionNCT00434967AstraZeneca2,207
撤回
4 期
Aliskiren Study of Safety and Efficacy in Senior HypertensivesHypertensionNCT01922141Novartis Pharmaceuticals